Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control
Year: 2015
Type: article
Study design: Case Report
Abstract: Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with immunosuppressants such as steroids or the anti-TNFα antibody, infliximab. We describe two patients with advanced melanoma treated with ipilimumab. Both suffered from severe immune related side effects and required prolonged immunosuppression with steroids and/or infliximab. Both patients recovered and in spite of the immune suppression, demonstrate clinical evidence of tumor control. This argues that distinct immunological effector functions control nosocomial infection and tumor, respectively. To our knowledge, these are also the first two case reports of pneumocystis pneumonia in this setting.
Source: OncoImmunology
Authors: Edurne Arriola, Matthew Wheater, Radhika Krishnan, James Smart, Vipul Foria, Christian Ottensmeier
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,913
Funder: Cancer Research UK
Awards: G3333659984, G3769281585
OpenAlex ID: W1898612748
